EMA Authorised: Yondelis (trabectedin) — Pharma Mar S.A.

View source ↗

Summary

EU marketing authorisation granted for Yondelis (trabectedin) for ovarian neoplasms and soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms
• Soft Tissue Sarcoma

Drugs mentioned

• Yondelis (trabectedin)

Snippet

Status: Authorised. Therapeutic area: Ovarian Neoplasms;Sarcoma. MAH: Pharma Mar S.A.. Decision date: 13/02/2025